Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
The diagnosis of diabetes mellitus in clinical practice has been mainly based on the measurement of glucose levels in blood. Growing evidence, including results from a new large-scale population study, however, strongly suggests that the assessment of glycated hemoglobin levels has advantages over measurement of glucose levels in predicting the risk of developing diabetes or cardiovascular disease.
Wareham
Nicholas J
NJ
Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. njw1004@mrc-epid.cam.ac.uk
Pfister
Roman
R
D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D048909:Diabetes Complications / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors
D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human